CASI Pharmaceuticals (CASIF) Operating Expenses (2022 - 2025)

CASI Pharmaceuticals has reported Operating Expenses for 4 years, with the latest figure at $16.5 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses fell 80.66% year-over-year to $16.5 million; the trailing twelve-month figure through Dec 2025 stood at -$22.0 million (down 143.43% YoY), and the FY2025 full-year result was $55.1 million, up 8.5% from the prior year.
• Operating Expenses for Q4 2025 stood at $16.5 million, up from -$11.4 million in the prior quarter.
• The five-year high for Operating Expenses was $85.4 million in Q4 2024, with the low at -$96.7 million in Q4 2022.
• Historically, Operating Expenses has averaged $783562.5 across 4 years, with a median of $8.9 million in 2023.
• The largest YoY upside for Operating Expenses was 1040.69% in 2024 against a maximum downside of 221.62% in 2024.
• CASI Pharmaceuticals' Operating Expenses stood at -$96.7 million in 2022, then surged by 107.74% to $7.5 million in 2023, then surged by 1040.69% to $85.4 million in 2024, then plunged by 80.66% to $16.5 million in 2025.
• The last three Operating Expenses figures came in at $16.5 million (Q4 2025), -$11.4 million (Q3 2025), and -$13.2 million (Q2 2025), per Business Quant data.